Gide advises the underwriters on the EUR 31.5 million IPO of MaaT Pharma on the regulated market of Euronext in Paris
9 November 2021
Deals | France | USA | Banking & Finance
Gide has advised Kempen, Portzamparc and KBC Securities on the initial public offering of MaaT Pharma on the regulated market of Euronext in Paris, for an estimated total gross amount of EUR 31.5 million.
MaaT Pharma is a French clinical-stage biotech company and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival rates of patients with cancer. MaaT Pharma's initial public offering on Euronext Paris is the first listing of a company developing microbiome-based drugs in continental Europe.
The team was led by partner Arnaud Duhamel and counsel Guilhem Richard, working with associates Louis Ravaud, Mélanie Simon-Giblin and Madelna Koyassambia. Partner Melinda Arsouze and associate Scott Logan worked on aspects of US law. Associates Caroline Wehner, Aurélie Pacaud and Luca Chevallier advised on IP/IT aspects, while counsel Alexandre Bochu advised on tax law aspects.